Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase III trial compares minimally invasive surgery (MIS) to laparotomy in treating patients with stage IIIC-IV ovarian, primary peritoneal, or fallopian tube cancer who are receiving chemotherapy before and after surgery (neoadjuvant chemotherapy). MIS is a surgical procedure that uses small incision(s) and is intended to produce minimal blood loss and pain for the patient. Laparotomy is a surgical procedure which allows the doctors to remove some or all of the tumor and check if the disease has spread to other organs in the body. MIS may work the same or better than standard laparotomy after chemotherapy in prolonging the return of the disease and/or improving quality of life after surgery.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Zaawansowany rak jajnika, otrzewnej lub jajowodu (stadium IIIC lub IV)
- •Przejście 3-4 cykli chemioterapii przed operacją
- •Całkowite ustąpienie choroby poza jamą brzuszną potwierdzone badaniami obrazowymi
- •Znormalizowany poziom markera CA-125 lub wartość ≤500 j.m.
- •Operacja zaplanowana w ciągu 6 tygodni od ostatniego cyklu chemioterapii
- •Ogólny stan zdrowia umożliwiający operację (ECOG 0-2)
- •Ujemny test ciążowy przeprowadzony do 14 dni przed operacją
✗ Disqualifies
- •Guz nienadający się do małoinwazyjnego usunięcia na podstawie badań przedoperacyjnych (CT, PET-CT, MRI)
- •Brak poprawy w ilości płynu w brzuchu podczas chemioterapii (poza śladową ilością)
- •Guz dotyczący jelita cienkiego lub żołądka
- •Guz dotyczący jelita grubego lub odbytnika
- •Inne aktywne nowotwory w ciągu ostatnich 5 lat (z wyjątkiem czerniaków skóry)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 14, 2026
- Sex
- Female only
Therapies / drugs in trial
Locations (19)
University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, United States
Cleveland Clinic Foundation - Florida
Weston, United States
Massachusetts General Hospital
Boston, United States
Dana Farber Cancer Institute
Boston, United States
NYU Langone Health
Mineola, United States
Columbia University Medical Center
New York, United States
Duke
Durham, United States
Cleveland Clinic
Cleveland, United States
St. Luke's University Health Network
Bethlehem, United States
Lyndon Baines Johnson General
Houston, United States
Houston Methodist
Houston, United States
M D Anderson Cancer Center
Houston, United States
University of Wisconsin Carbone Cancer Center
Madison, United States
Arthur J.E. Child Comprehensive Cancer Centre - Calgary
Calgary, Canada
University Health Network - Princess Margaret Cancer Centre
Toronto, Canada
Sant'Orsola Hospital di Bologna
Bologna, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Rome, Italy
Instituto Nacional de Cancerología (Mexico)
Tlalpan, Mexico
Amsterdam UMC - Locatie AMC | H5Zuid 154
Amsterdam, Netherlands
Trial contact
Jose A. Rauh-Hain, MD, MPH
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/15/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.